2024년에 34억 달러로 추정되는 생어 시퀀싱 세계 시장은 2024년부터 2030년까지 CAGR 17.5%로 성장하여 2030년에는 89억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 샷건 시퀀싱은 CAGR 16.3%를 기록하며 분석 기간 종료까지 54억 달러에 달할 것으로 예측됩니다. 타겟 유전자 시퀀싱 부문의 성장률은 분석 기간 동안 CAGR 19.1%로 추정됩니다.
미국 시장은 8억 9,420만 달러로 추정, 중국은 CAGR 16.6%로 성장할 것으로 예측
미국의 생어 시퀀싱 시장은 2024년에 8억 9,420만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 14억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 16.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 15.9%와 15.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.0%로 성장할 것으로 예측됩니다.
세계의 "생어 시퀀싱" 시장 - 주요 동향과 촉진요인 정리
유전체학이 주도하는 세상에서 싱어 시퀀싱이 계속 중요한 이유는 무엇일까?
차세대 시퀀싱(NGS) 플랫폼의 등장에도 불구하고, Sanger 시퀀싱은 탁월한 정확성, 단순성, 특정 애플리케이션에 대한 비용 효율성으로 인해 그 관련성을 유지하고 있습니다. 시퀀싱 검증, 단일 유전자 진단 및 소규모 연구 프로젝트에서 여전히 표준으로 사용되고 있습니다. 이 방법은 임상 유전체학에서 하이스루풋 방법으로 확인된 변이를 확인하기 위해 높은 평가를 받고 있습니다. 싱어 시퀀싱은 종종 1000 염기쌍에 이르는 길고 충실한 리드를 제공할 수 있기 때문에 연구자들이 선호하며, 표적 영역의 삽입, 결실 및 돌연변이 검출에 가장 적합한 방법입니다. 진단 실험실에서는 희귀 질환 및 유전성 질환의 유전자 검사에 널리 사용되고 있으며, Sanger의 최소한의 데이터 출력은 특히 자원이 제한된 환경에서 저장 및 분석을 단순화합니다. 또한 복잡한 NGS 워크플로우에 비해 처리 시간이 빠르다는 장점도 있습니다. 유전체학 시장이 수의학, 농업, 미생물학 분야로 다양화되는 가운데, 생어 시퀀싱의 견고성은 필수적인 보완 기술이 되고 있습니다. 모세관 전기영동 시스템에 대한 적응성과 기존 실험실 인프라와의 통합성은 기존 사용 사례와 새로운 사용 사례 모두에서 그 적용을 계속 지원하고 있습니다.
기술은 어떻게 생어 시퀀싱의 정확성과 접근성을 향상시키는가?
DNA 추출, PCR 클린업 및 반응 준비의 자동화는 수작업으로 인한 실수를 최소화하고 시료 처리의 효율성을 향상시켰으며, DNA 추출, PCR 클린업 및 반응 준비의 자동화는 수작업으로 인한 실수를 최소화하고 시료 처리의 효율성을 향상시켰습니다. 염료 터미네이터 화학 및 모세관 전기영동 시스템의 개선으로 신호의 선명도, 속도 및 데이터 분해능이 향상되었습니다. 소형 벤치탑 시퀀서로 소규모 실험실이나 클리닉에서 분산형 시퀀싱이 가능해졌습니다. 또한, 클라우드 기반 바이오인포매틱스 플랫폼과의 통합으로 데이터 분석, 해석, 보고서 작성에 전문가가 아니어도 사용할 수 있게 되었으며, AI 툴을 사용하여 저빈도 변이체를 보다 안정적으로 검출할 수 있게 되었습니다. 시약의 소형화는 시료당 비용 절감에 도움이 되고, 오픈 소스 실험 장비는 교육 기관에서 저비용으로 도입할 수 있도록 돕습니다. 시료의 바코드 태깅은 더 높은 수준의 다중화를 가능하게 하여 실험실의 생산성을 향상시킵니다. 또한, 실시간 모니터링 도구는 모든 단계에서 품질 관리를 보장합니다. 그 결과, 생어 시퀀싱은 더 이상 단순한 수작업 실험실 절차가 아닌, 보다 광범위한 유전체학 생태계에 적합한 반자동화된 지능형 플랫폼으로 진화하고 있습니다.
생어 시퀀싱 수요가 가장 빠르게 증가하고 있는 분야는?
생어 시퀀싱은 정확성과 확인이 가장 중요한 특정 산업에서 새로운 수요가 발생하고 있습니다. 임상 진단에서는 특히 암 소인 및 희귀 질환 패널에서 생식세포 계열 변이 확인 검사에 자주 사용됩니다. 약리유전체학에서는 정확한 유전형 분석이 맞춤형 치료에 필수적이며, 그 역할이 확대되고 있습니다. 농업유전체학도 성장 분야로, 작물의 유전자형 판별, 형질 확인, 육종 프로그램에 활용되고 있습니다. 미생물학에서는 병원체 동정, 항생제 내성 분석, 플라스미드 검증에 사용되고 있습니다. 수의학에서는 혈통이 있는 동물의 유전자 검사 및 질병 추적을 위해 점점 더 많은 수의학자들이 싱거를 사용하고 있습니다. 법의학 연구소에서는 고품질의 리드 출력으로 인해 미토콘드리아 DNA 분석에 이 방법을 계속 사용하고 있습니다. 교육 기관에서도 신뢰성과 사용 편의성 때문에 시퀀싱의 기초를 배우는 학생들의 교육에 Sanger 시스템을 사용하고 있습니다. 계약 연구 기관(CRO)에 대한 시퀀싱 서비스 아웃소싱의 증가는 시장의 안정적인 수요를 더욱 촉진하고 있습니다. 이러한 분야 고유의 요구사항은 현대 유전체학에서 기초 기술로서 Sanger의 고유한 역할을 강조하고 있습니다.
생어 시퀀싱 시장의 성장은 몇 가지 요인에 의해 발생합니다...
생어 시퀀싱 시장의 확대는 지속적인 기술적 매력과 변화하는 업계 니즈의 결합에 의해 뒷받침되고 있습니다. 특히 정밀의료에서 동반진단이 확산됨에 따라 임상 진단에서 신뢰할 수 있는 확인 검사에 대한 수요가 지속적으로 증가하고 있습니다. 학계와 정부 기관의 연구 이니셔티브 증가도 시장 확대에 박차를 가하고 있습니다. 비용 효율성과 설치의 용이성으로 인해 Sanger는 특히 개발도상국의 저처리량 실험실에서 선택되고 있으며, NGS 데이터세트의 복잡성으로 인해 최종 검증을 위해 Sanger 시퀀싱에 대한 의존도가 높아지고 있습니다. 규제 기관은 입증된 재현성과 정확성으로 인해 승인 시 싱거 데이터를 선호하고 있습니다. 실험실 자동화 및 벤치탑 시퀀싱 장비에 대한 지속적인 투자로 인해 기술의 확장성이 증가하고 있습니다. 또한, 시장은 병원, CRO, 분자진단 기업 간의 협력 관계 확대의 혜택을 누리고 있습니다. Sanger 시퀀싱은 감염병 감시에서 식물 육종에 이르기까지 광범위한 유전체 툴킷의 보완적인 솔루션으로 번창하고 있습니다.
부문
유형(샷건 시퀀싱, 타겟 유전자 시퀀싱, 기타 유형), 용도(진단, 맞춤형 의료, 법의학, 기타 용도), 최종 용도(정부 연구기관, 진단 실험실, 제약·바이오테크놀러지 기업, 기타 최종 용도)
조사 대상 기업 사례(총 42개사)
AAT Bioquest
Azenta Life Sciences(GENEWIZ)
BaseClear
BGI Genomics
Eurofins Genomics
GenScript
Illumina
LGC Biosearch Technologies
Macrogen
MCLAB
Microsynth AG
Nucleics
Psomagen
QIAGEN
Roche Applied Science
SeqLab
Source BioScience
Synlab
Thermo Fisher Scientific
Zymo Research
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월 : 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월 : 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석:
미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국
업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSM
영문 목차
영문목차
Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030
The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR
The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.
Global "Sanger Sequencing" Market - Key Trends & Drivers Summarized
Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?
Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.
How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?
Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.
In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?
Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it's frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.
The Growth In The Sanger Sequencing Market Is Driven By Several Factors...
The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.
SCOPE OF STUDY:
The report analyzes the Sanger Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
AAT Bioquest
Azenta Life Sciences (GENEWIZ)
BaseClear
BGI Genomics
Eurofins Genomics
GenScript
Illumina
LGC Biosearch Technologies
Macrogen
MCLAB
Microsynth AG
Nucleics
Psomagen
QIAGEN
Roche Applied Science
SeqLab
Source BioScience
Synlab
Thermo Fisher Scientific
Zymo Research
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Sanger Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Continued Use in Targeted DNA Sequencing Applications Sustains Demand for Sanger Sequencing
Clinical Diagnostics and Genetic Validation Workflows Strengthen Business Case for Precision Sequencing
Pharma and Biotech R&D Activities Throw the Spotlight on Sangers Reliability in Mutation Detection
Growing Preference for Low-Throughput, High-Accuracy Techniques in Niche Applications Drives Adoption
Cost-Effectiveness in Academic and Clinical Labs Sustains Long-Term Relevance of Sanger Platforms
Rising Prevalence of Genetic Disorders Accelerates Use in Confirmatory Testing
Expansion of Outsourced Sequencing Services Creates New Demand from Research Institutions
Next-Generation Sequencing Limitations in Long Homopolymer Regions Create Opportunities for Sanger
Regulatory Compliance in Clinical Genomics Favors Established and Validated Technologies
Integration with NGS Workflows for Hybrid Pipelines Expands Market Potential
Low Entry Cost and Training Requirements Sustain Adoption in Emerging Markets and Universities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Sanger Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Shotgun Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Shotgun Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Targeted Gene Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Targeted Gene Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Forensics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 23: World 6-Year Perspective for Forensics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 28: USA Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: USA 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 30: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: USA 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 34: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Canada 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 36: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: Canada 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
JAPAN
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 40: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 41: Japan 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 42: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 43: Japan 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
CHINA
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 46: China Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 47: China 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 48: China Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 49: China 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
EUROPE
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 52: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 53: Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 54: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 55: Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
FRANCE
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 58: France Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 59: France 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 60: France Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 61: France 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
GERMANY
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 64: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 65: Germany 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 66: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 67: Germany 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
ITALY
TABLE 70: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 71: Italy 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 72: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 73: Italy 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
UNITED KINGDOM
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 76: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 77: UK 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 78: UK Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 79: UK 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
REST OF EUROPE
TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 83: Rest of Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 85: Rest of Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Rest of Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
ASIA-PACIFIC
Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 89: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 91: Asia-Pacific 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
REST OF WORLD
TABLE 94: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 95: Rest of World 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
TABLE 96: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 97: Rest of World 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of World 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
